Invention Grant
- Patent Title: Method of treating gastric cancer with anti-FGFR2-IIIb antibodies and modified FOLFOX6 chemotherapy
-
Application No.: US16613579Application Date: 2018-05-15
-
Publication No.: US11091555B2Publication Date: 2021-08-17
- Inventor: Helen L. Collins , James Hnatyszyn , Hong Xiang , Xiang Zhang
- Applicant: Five Prime Therapeutics, Inc.
- Applicant Address: US CA South San Francisco
- Assignee: Five Prime Therapeutics, Inc.
- Current Assignee: Five Prime Therapeutics, Inc.
- Current Assignee Address: US CA South San Francisco
- Agency: McNeill Baur PLLC
- International Application: PCT/US2018/032757 WO 20180515
- International Announcement: WO2018/213304 WO 20181122
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61P35/04 ; A61P35/00 ; A61K9/00 ; A61K31/282 ; A61K31/513 ; A61K31/519 ; A61K39/395 ; A61K39/00
Abstract:
This application relates to uses of antibodies against fibroblast growth factor receptor 2 (FGFR2), including antibodies against the FGFR2 isoform FGFR2-IIIb (also known as FGFR2b), in treatment of certain cancers in combinations with mFOLFOX6 chemotherapy.
Public/Granted literature
- US20200079856A1 Anti-FGFR2 Antibodies in Combination with Chemotherapy Agents in Cancer Treatment Public/Granted day:2020-03-12
Information query
